Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Cash from Financing Activities (2016 - 2025)

Avalo Therapeutics' Cash from Financing Activities history spans 12 years, with the latest figure at $687000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 98.99% year-over-year to $687000.0; the TTM value through Dec 2025 reached $14.6 million, down 91.7%, while the annual FY2025 figure was $14.6 million, 91.7% down from the prior year.
  • Cash from Financing Activities reached $687000.0 in Q4 2025 per AVTX's latest filing, down from $14.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $108.6 million in Q1 2024 to a low of -$14.8 million in Q2 2022.
  • Average Cash from Financing Activities over 5 years is $19.2 million, with a median of $5.7 million recorded in 2023.
  • The largest YoY upside for Cash from Financing Activities was 6770800.0% in 2024 against a maximum downside of 178.93% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $76000.0 in 2021, then grew by 7.89% to $82000.0 in 2022, then crashed by 98.78% to $1000.0 in 2023, then soared by 6770800.0% to $67.7 million in 2024, then tumbled by 98.99% to $687000.0 in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Cash from Financing Activities are $687000.0 (Q4 2025), $14.4 million (Q3 2025), and -$469000.0 (Q2 2025).